Cargando…
OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802649/ http://dx.doi.org/10.1016/j.esmoop.2022.100695 |
| _version_ | 1784861720160763904 |
|---|---|
| author | Wanchaijiraboon, P. Teeyapun, N. Luangdilok, S. Wanlapakorn, N. Sainamthip, P. Pakvisal, N. Namkanisorn, T. Sriuranpong, V. Phaibulvatanapong, E. Veranitinun, R. Inthasuwan, P. Sartsuk, C. Phongwan, R. Angspatt, P. Wongchanapat, P. Poovorawan, Y. Tanasanvimon, S. |
| author_facet | Wanchaijiraboon, P. Teeyapun, N. Luangdilok, S. Wanlapakorn, N. Sainamthip, P. Pakvisal, N. Namkanisorn, T. Sriuranpong, V. Phaibulvatanapong, E. Veranitinun, R. Inthasuwan, P. Sartsuk, C. Phongwan, R. Angspatt, P. Wongchanapat, P. Poovorawan, Y. Tanasanvimon, S. |
| author_sort | Wanchaijiraboon, P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9802649 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98026492023-01-04 OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study Wanchaijiraboon, P. Teeyapun, N. Luangdilok, S. Wanlapakorn, N. Sainamthip, P. Pakvisal, N. Namkanisorn, T. Sriuranpong, V. Phaibulvatanapong, E. Veranitinun, R. Inthasuwan, P. Sartsuk, C. Phongwan, R. Angspatt, P. Wongchanapat, P. Poovorawan, Y. Tanasanvimon, S. ESMO Open Article Published by Elsevier Ltd 2022-12 2022-12-30 /pmc/articles/PMC9802649/ http://dx.doi.org/10.1016/j.esmoop.2022.100695 Text en Copyright © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Wanchaijiraboon, P. Teeyapun, N. Luangdilok, S. Wanlapakorn, N. Sainamthip, P. Pakvisal, N. Namkanisorn, T. Sriuranpong, V. Phaibulvatanapong, E. Veranitinun, R. Inthasuwan, P. Sartsuk, C. Phongwan, R. Angspatt, P. Wongchanapat, P. Poovorawan, Y. Tanasanvimon, S. OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study |
| title | OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study |
| title_full | OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study |
| title_fullStr | OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study |
| title_full_unstemmed | OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study |
| title_short | OP12 Durability and immunogenicity after two doses of ChAdOx1 nCov-19 among the type of cancer treatment in oncologic patients: A prospective, multicenter observational study |
| title_sort | op12 durability and immunogenicity after two doses of chadox1 ncov-19 among the type of cancer treatment in oncologic patients: a prospective, multicenter observational study |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802649/ http://dx.doi.org/10.1016/j.esmoop.2022.100695 |
| work_keys_str_mv | AT wanchaijiraboonp op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT teeyapunn op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT luangdiloks op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT wanlapakornn op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT sainamthipp op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT pakvisaln op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT namkanisornt op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT sriuranpongv op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT phaibulvatanaponge op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT veranitinunr op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT inthasuwanp op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT sartsukc op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT phongwanr op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT angspattp op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT wongchanapatp op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT poovorawany op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy AT tanasanvimons op12durabilityandimmunogenicityaftertwodosesofchadox1ncov19amongthetypeofcancertreatmentinoncologicpatientsaprospectivemulticenterobservationalstudy |